ClinicalTrials.gg
CompletedNCT02383966CHANGE2Updated May 13, 2022Results posted

Phase III Trial to Assess Efficacy and Safety of Cetuximab for the Treatment of Chinese Participants With Head and Neck Cancer

A Phase 3 interventional study of Cetuximab and Cisplatin/Carboplatin in Carcinoma, Squamous Cell of Head and Neck, sponsored by Merck KGaA, Darmstadt, Germany. Completed at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-05-13.

Sponsored by Merck KGaA, Darmstadt, Germany · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
243
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 86 studies testing cetuximab in Squamous Cell Carcinoma of Head and Neck — 11 open to participants now, 19 under way, 7 of them phase 3. Cetuximab · Squamous Cell Carcinoma of Head and Neck.

Enrollment
12th of 84
243 · median 46
Started
2015
with 5 others
Phase 3
16 of 86
4 open now
Registered
58th of 86
by date
Lead sponsor
4 of 86
Merck KGaA, Darmstadt, Germany

Among the 86 studies testing cetuximab in Squamous Cell Carcinoma of Head and Neck, this one is the 12th largest by enrollment of the 84 interventional ones that give a count, is one of 6 that started in 2015, is one of 16 in phase 3, and was the 58th registered.

Squamous Cell Carcinoma of Head and Neck

2,019 studies on the registry are indexed under Squamous Cell Carcinoma of Head and Neck; 573 are open to participants now.

Browse Squamous Cell Carcinoma of Head and Neck studies →

Open to participants now

11 of the 86 studies testing cetuximab in Squamous Cell Carcinoma of Head and Neck are open now, in 4 countries. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 11 open studies →

About cetuximab

Cetuximab: first FDA approval 2004 (ERBITUX), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 435 Squamous Cell Carcinoma of Head and Neck studies recruiting now, 311 (71%) set no upper age limit and 87 (20%) stop at 75 or younger; 5 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 86 studies testing cetuximab in Squamous Cell Carcinoma of Head and Neck, or all of them as a file.
02

Study summary

This trial aimed to assess efficacy and safety of cetuximab when given in combination with chemotherapy compared with chemotherapy alone in Chinese participants with recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN) as the first-line treatment.

03

Conditions studied

  • Carcinoma, Squamous Cell of Head and Neck
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or cytologically confirmed diagnosis of SCCHN
  • Recurrent and/or SCCHN, not suitable for local-regional treatment
  • Presence of at least 1 according to Version 1.1
  • Signed written before any trial-related activities are carried out
  • (ECOG) performance status of 0 or 1
  • Other protocol-defined inclusion criteria could apply

Exclusion criteria

Exclusion Criteria:

  • Prior systemic chemotherapy, except if given as part of multimodal treatment for locally advanced disease, that was completed within 6 months before randomization
  • Surgery (excluding prior for diagnosis) or irradiation within 4 weeks before trial entry
  • Previous treatment with monoclonal antibody or signal transduction inhibitors targeting epidermal growth factor receptor
  • Nasopharyngeal carcinoma
  • Known central nervous system and/or
  • Medical or psychological condition that would not permit the participant to complete the trial or sign
  • Legal incapacity or limited legal capacity
  • Other protocol-defined exclusion criteria could apply
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
243 participants (actual)

Study arms

  • Experimental
    Cetuximab + Cisplatin/Carboplatin + 5-Fluorouracil

    Drug: Cetuximab · Drug: Cisplatin/Carboplatin · Drug: 5-fluorouracil

  • Active comparator
    Cisplatin/Carboplatin + 5-Flurouracil

    Drug: Cisplatin/Carboplatin · Drug: 5-fluorouracil

Interventions

  • Participants received Cetuximab as an intravenous infusion at an initial dose of 400 milligrams per square meter (mg/m\^2) on Day 1 and a subsequent dose of 250 mg/m\^2 on Day 8 and Day 15 of each 21-day treatment cycle.

    Also known as: Erbitux

  • DrugCisplatin/Carboplatin

    Drug pages: Cisplatin · Carboplatin

    Cisplatin or Carboplatin (at an equivalent dose in case of intolerability of cisplatin) was administered at a dose of 75 mg/m\^2 as an intravenous infusion on Day 1 of each 21-day treatment cycle.

  • Participants received 5-fluorouracil (FU) at a dose of 750 mg/m\^2/day as a continuous intravenous infusion over 24 hours a day from Day 1 to Day 5 of each 21-day treatment cycle.

    Also known as: 5-FU

06

What researchers measure

Primary outcomes

  1. Progression-free Survival (PFS) Time, as Assessed by an Independent Review Committee (IRC)

    PFS time was defined as the time in months from the date of randomization until first observation of PD (based on imaging as assessed by IRC), or death due to any cause when death occurs within 60 days after the last tumor assessment or randomization (whichever is later). PD is defined as at least a 20 percent (%) increase in the sum of diameters of target lesions, taking as reference the smallest sum on trial; and/or unequivocal progression of existing non-target lesions and/or the presence of new lesions. The sum must also demonstrate an absolute increase of at least 5 millimeter. PFS was measured using Kaplan-Meier (KM) estimates.

    Time frame: Every 6 weeks starting from the date of randomization until occurrence of PD, assessed up to data-cutoff (904 days)

Secondary outcomes

  1. Progression-free Survival (PFS) Time, as Assessed by the Investigator

    PFS time was defined as the time in months from the date of randomization until first observation of PD (radiologically confirmed by Investigator), or death due to any cause when death occurs within 60 days after the last tumor assessment or randomization (whichever is later). PD is defined as at least a 20 percent (%) increase in the sum of diameters of target lesions, taking as reference the smallest sum on trial; and/or unequivocal progression of existing non-target lesions and/or the presence of new lesions. The sum must also demonstrate an absolute increase of at least 5 millimeter. PFS was measured using Kaplan-Meier (KM) estimates.

    Time frame: Every 6 weeks starting from the date of randomization until occurrence of PD, assessed up to data-cutoff (904 days)

  2. Overall Survival (OS) Time

    The OS time was defined as the time from randomization to the date of death. If a participant was alive at the time of analysis, survival time was censored at the last date when the participant was known to be alive. If this date was after data cut-off, participants were censored at the date of data cut-off. OS was measured using Kaplan-Meier (KM) estimates.

    Time frame: Time from date of randomization up to data cutoff (assessed up to 904 days)

  3. Best Overall Response Rate (ORR)

    The Best ORR was based on imaging and classified according to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 criteria. The BOR rate was defined as the number of participants whose BOR was either complete response (CR) or partial response (PR), relative to the number of participants belonging to the trial set of interest. CR was defined as disappearance of all target and non-target lesions. Any pathological lymph nodes (whether target or non-target) must had reduction in short axis to less than (\<) 10 millimeters (mm). PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

    Time frame: Every 6 weeks starting from the date of randomization until occurrence of PD, assessed up to data-cutoff (904 days)

  4. Disease Control Rate (DCR)

    The DCR was based on imaging and classified according to RECIST Version 1.1 criteria. The DCR was defined as the number of participants whose Best Overall Response is either CR, PR or stable disease (SD), divided by the number of participants belonging to the trial set of interest multiplied by 100. CR was defined as disappearance of all target and non-target lesions. Any pathological lymph nodes (whether target or non-target) must had reduction in short axis to less than (\<) 10 millimeters (mm). PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on trial.

    Time frame: Every 6 weeks starting from the date of randomization until occurrence of PD, assessed up to data-cutoff (904 days)

  5. Duration of Response (DOR)

    DOR was determined for participants whose BOR was either CR or PR. It was defined as the time from the first assessment of CR or PR until the event defining PFS time. PFS time was defined as the time in months from the date of randomization until first observation of PD (based on imaging as assessed by IRC), or death due to any cause when death occurs within 60 days after the last tumor assessment or randomization (whichever is later). CR was defined as disappearance of all target and non-target lesions. Any pathological lymph nodes (whether target or non-target) must had reduction in short axis to less than (\<) 10 millimeters (mm). PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

    Time frame: Every 6 weeks starting from the date of randomization until occurrence of PD, assessed up to data-cutoff (904 days)

  6. Number of Participants With Treatment Emergent Adverse Events (TEAEs), Treatment Emergent Serious Adverse Events (TESAEs), Treatment Emergent Adverse Events Leading to Death and AEs Leading to Discontinuation

    An Adverse event (AE) was defined as any unfavorable and unintended sign, symptom, or disease temporally associated with the use of study drug or worsening of pre-existing medical condition, whether or not related to study drug. A serious adverse event (SAE) was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. Treatment-emergent are events between first dose of study drug that were absent before treatment or that worsened relative to pre-treatment state up to 30 days after last administration. TEAEs included both Serious TEAEs and non-serious TEAEs.

    Time frame: Time from date of randomization up to data cutoff (assessed up to 904 days)

07

Results

Posted Apr 16, 2019

Participant flow

First participant signed informed consent: 31 Jul 2015, Clinical data cut-off: 19 Jan 2018.

Participant flow — Overall Study
MilestoneCetuximab + Cisplatin/Carboplatin + 5-FluorouracilCisplatin/Carboplatin + 5-Flurouracil
Started16479
Completed13872
Not completed267
Withdrew: Ongoing at clinical cut-off date254
Withdrew: Randomized, but not treated13

Outcome measures

PrimaryProgression-free Survival (PFS) Time, as Assessed by an Independent Review Committee (IRC)

PFS time was defined as the time in months from the date of randomization until first observation of PD (based on imaging as assessed by IRC), or death due to any cause when death occurs within 60 days after the last tumor assessment or randomization (whichever is later). PD is defined as at least a 20 percent (%) increase in the sum of diameters of target lesions, taking as reference the smallest sum on trial; and/or unequivocal progression of existing non-target lesions and/or the presence of new lesions. The sum must also demonstrate an absolute increase of at least 5 millimeter. PFS was measured using Kaplan-Meier (KM) estimates.

Time frame:
Every 6 weeks starting from the date of randomization until occurrence of PD, assessed up to data-cutoff (904 days)
Reported as:
Median · months
Progression-free Survival (PFS) Time, as Assessed by an Independent Review Committee (IRC)
monthsCetuximab + Cisplatin/Carboplatin + 5-FluorouracilCisplatin/Carboplatin + 5-Flurouracil
Progression-free Survival (PFS) Time, as Assessed by an Independent Review Committee (IRC)5.5 (5.4 to 5.6)4.2 (3.0 to 5.3)
Statistical analysis
  • Cetuximab + Cisplatin/Carboplatin + 5-Fluorouracil vs Cisplatin/Carboplatin + 5-Flurouracil · Hazard ratio (hr): 0.566 · 95% CI 0.400 to 0.803
SecondaryProgression-free Survival (PFS) Time, as Assessed by the Investigator

PFS time was defined as the time in months from the date of randomization until first observation of PD (radiologically confirmed by Investigator), or death due to any cause when death occurs within 60 days after the last tumor assessment or randomization (whichever is later). PD is defined as at least a 20 percent (%) increase in the sum of diameters of target lesions, taking as reference the smallest sum on trial; and/or unequivocal progression of existing non-target lesions and/or the presence of new lesions. The sum must also demonstrate an absolute increase of at least 5 millimeter. PFS was measured using Kaplan-Meier (KM) estimates.

Time frame:
Every 6 weeks starting from the date of randomization until occurrence of PD, assessed up to data-cutoff (904 days)
Reported as:
Median · months
Progression-free Survival (PFS) Time, as Assessed by the Investigator
monthsCetuximab + Cisplatin/Carboplatin + 5-FluorouracilCisplatin/Carboplatin + 5-Flurouracil
Progression-free Survival (PFS) Time, as Assessed by the Investigator5.5 (5.5 to 5.7)4.6 (2.9 to 5.5)
Statistical analysis
  • Cetuximab + Cisplatin/Carboplatin + 5-Fluorouracil vs Cisplatin/Carboplatin + 5-Flurouracil · Hazard ratio (hr): 0.568 · 95% CI 0.406 to 0.795
SecondaryOverall Survival (OS) Time

The OS time was defined as the time from randomization to the date of death. If a participant was alive at the time of analysis, survival time was censored at the last date when the participant was known to be alive. If this date was after data cut-off, participants were censored at the date of data cut-off. OS was measured using Kaplan-Meier (KM) estimates.

Time frame:
Time from date of randomization up to data cutoff (assessed up to 904 days)
Reported as:
Median · months
Overall Survival (OS) Time
monthsCetuximab + Cisplatin/Carboplatin + 5-FluorouracilCisplatin/Carboplatin + 5-Flurouracil
Overall Survival (OS) Time10.2 (9.3 to 11.5)8.4 (6.5 to 9.9)
Statistical analysis
  • Cetuximab + Cisplatin/Carboplatin + 5-Fluorouracil vs Cisplatin/Carboplatin + 5-Flurouracil · Hazard ratio (hr): 0.705 · 95% CI 0.502 to 0.991
SecondaryBest Overall Response Rate (ORR)

The Best ORR was based on imaging and classified according to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 criteria. The BOR rate was defined as the number of participants whose BOR was either complete response (CR) or partial response (PR), relative to the number of participants belonging to the trial set of interest. CR was defined as disappearance of all target and non-target lesions. Any pathological lymph nodes (whether target or non-target) must had reduction in short axis to less than (\<) 10 millimeters (mm). PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

Time frame:
Every 6 weeks starting from the date of randomization until occurrence of PD, assessed up to data-cutoff (904 days)
Reported as:
Number · percentage of participants
Best Overall Response Rate (ORR)
percentage of participantsCetuximab + Cisplatin/Carboplatin + 5-FluorouracilCisplatin/Carboplatin + 5-Flurouracil
Best Overall Response Rate (ORR)50 (42.1 to 57.9)26.6 (17.3 to 37.7)
Statistical analysis
  • Cetuximab + Cisplatin/Carboplatin + 5-Fluorouracil vs Cisplatin/Carboplatin + 5-Flurouracil · Odds ratio (or): 2.76 · 95% CI 1.52 to 5.45
SecondaryDisease Control Rate (DCR)

The DCR was based on imaging and classified according to RECIST Version 1.1 criteria. The DCR was defined as the number of participants whose Best Overall Response is either CR, PR or stable disease (SD), divided by the number of participants belonging to the trial set of interest multiplied by 100. CR was defined as disappearance of all target and non-target lesions. Any pathological lymph nodes (whether target or non-target) must had reduction in short axis to less than (\<) 10 millimeters (mm). PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on trial.

Time frame:
Every 6 weeks starting from the date of randomization until occurrence of PD, assessed up to data-cutoff (904 days)
Reported as:
Number · percentage of participants
Disease Control Rate (DCR)
percentage of participantsCetuximab + Cisplatin/Carboplatin + 5-FluorouracilCisplatin/Carboplatin + 5-Flurouracil
Disease Control Rate (DCR)75.6 (68.3 to 82.0)59.5 (47.9 to 70.4)
Statistical analysis
  • Cetuximab + Cisplatin/Carboplatin + 5-Fluorouracil vs Cisplatin/Carboplatin + 5-Flurouracil · Odds ratio (or): 2.14 · 95% CI 1.15 to 3.95
SecondaryDuration of Response (DOR)

DOR was determined for participants whose BOR was either CR or PR. It was defined as the time from the first assessment of CR or PR until the event defining PFS time. PFS time was defined as the time in months from the date of randomization until first observation of PD (based on imaging as assessed by IRC), or death due to any cause when death occurs within 60 days after the last tumor assessment or randomization (whichever is later). CR was defined as disappearance of all target and non-target lesions. Any pathological lymph nodes (whether target or non-target) must had reduction in short axis to less than (\<) 10 millimeters (mm). PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

Time frame:
Every 6 weeks starting from the date of randomization until occurrence of PD, assessed up to data-cutoff (904 days)
Reported as:
Median · Weeks
Duration of Response (DOR)
WeeksCetuximab + Cisplatin/Carboplatin + 5-FluorouracilCisplatin/Carboplatin + 5-Flurouracil
Duration of Response (DOR)18.1 (13.1 to 20.3)13.9 (8.7 to 18.1)
SecondaryNumber of Participants With Treatment Emergent Adverse Events (TEAEs), Treatment Emergent Serious Adverse Events (TESAEs), Treatment Emergent Adverse Events Leading to Death and AEs Leading to Discontinuation

An Adverse event (AE) was defined as any unfavorable and unintended sign, symptom, or disease temporally associated with the use of study drug or worsening of pre-existing medical condition, whether or not related to study drug. A serious adverse event (SAE) was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. Treatment-emergent are events between first dose of study drug that were absent before treatment or that worsened relative to pre-treatment state up to 30 days after last administration. TEAEs included both Serious TEAEs and non-serious TEAEs.

Time frame:
Time from date of randomization up to data cutoff (assessed up to 904 days)
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Adverse Events (TEAEs), Treatment Emergent Serious Adverse Events (TESAEs), Treatment Emergent Adverse Events Leading to Death and AEs Leading to Discontinuation
ParticipantsCetuximab + Cisplatin/Carboplatin + 5-FluorouracilCisplatin/Carboplatin + 5-Flurouracil
TEAEs16375
TESAEs4621
TEAEs Leading to Death118
AEs Leading to Discontinuation278

Adverse events

Collected over Time from date of randomization up to data cutoff (assessed up to 904 days). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cetuximab + Cisplatin/Carboplatin + 5-Fluorouracil105/163 (64.4%)46/163 (28.2%)163/163 (100%)
Cisplatin/Carboplatin + 5-Flurouracil54/76 (71.1%)21/76 (27.6%)73/76 (96.1%)
Most frequent serious events
Showing 10 of 66
Most frequent serious events
EventCetuximab + Cisplatin/Carboplatin + 5-FluorouracilCisplatin/Carboplatin + 5-Flurouracil
Lung infectionInfections and infestations6/1634/76
Tumor haemorrhageNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/1633/76
DyspnoeaRespiratory, thoracic and mediastinal disorders5/1630/76
AnaemiaBlood and lymphatic system disorders1/1632/76
ThrombocytopeniaBlood and lymphatic system disorders2/1632/76
Upper respiratory tract infectionInfections and infestations0/1632/76
White blood cell count decreasedInvestigations0/1632/76
Obstructive airways disorderRespiratory, thoracic and mediastinal disorders0/1632/76
Febrile neutropeniaBlood and lymphatic system disorders0/1631/76
Atrial fibrillationCardiac disorders0/1631/76
Most frequent other events
Showing 10 of 62
Most frequent other events
EventCetuximab + Cisplatin/Carboplatin + 5-FluorouracilCisplatin/Carboplatin + 5-Flurouracil
NauseaGastrointestinal disorders93/16351/76
Weight decreasedInvestigations103/16331/76
VomitingGastrointestinal disorders60/16337/76
AnaemiaBlood and lymphatic system disorders73/16336/76
RashSkin and subcutaneous tissue disorders77/1631/76
ConstipationGastrointestinal disorders73/16331/76
Decreased appetiteMetabolism and nutrition disorders67/16334/76
White blood cell count decreasedInvestigations62/16325/76
NeutropeniaBlood and lymphatic system disorders58/16322/76
HypokalaemiaMetabolism and nutrition disorders56/16318/76

Baseline characteristics

Intention-to-treat (ITT) analysis set included all participants who were randomized to study treatment.

Age, Continuous
Age, Continuous(years)Cetuximab + Cisplatin/Carboplatin + 5-FluorouracilCisplatin/Carboplatin + 5-FlurouracilTotal
Mean57.1 ± 9.5257.0 ± 8.9957.1 ± 9.34
Sex: Female, Male
Sex: Female, Male(Participants)Cetuximab + Cisplatin/Carboplatin + 5-FluorouracilCisplatin/Carboplatin + 5-FlurouracilTotal
Female181230
Male14667213
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Cetuximab + Cisplatin/Carboplatin + 5-FluorouracilCisplatin/Carboplatin + 5-FlurouracilTotal
Hispanic or Latino000
Not Hispanic or Latino000
Unknown or Not Reported16479243
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Cetuximab + Cisplatin/Carboplatin + 5-FluorouracilCisplatin/Carboplatin + 5-FlurouracilTotal
American Indian or Alaska Native000
Asian16479243
Native Hawaiian or Other Pacific Islander000
Black or African American000
White000
More than one race000
Unknown or Not Reported000
08

Study locations

1 site
  • Research site
    Darmstadt, Germany
09

References and documents

Publications

  • Guo Y, Luo Y, Zhang Q, Huang X, Li Z, Shen L, Feng J, Sun Y, Yang K, Ge M, Zhu X, Wang L, Liu Y, He X, Bai C, Xue K, Zeng Y, Chang X, Chen W, Lin T. First-line treatment with chemotherapy plus cetuximab in Chinese patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: Efficacy and safety results of the randomised, phase III CHANGE-2 trial. Eur J Cancer. 2021 Oct;156:35-45. doi: 10.1016/j.ejca.2021.06.039. Epub 2021 Aug 18. PubMed 34418665 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2015 to primary completion in Jan 2018, 29 months.

Results were first posted in Apr 2019, 1 year 2 months after primary completion.

Of 78 phase 3 interventional studies under Squamous Cell Carcinoma of Head and Neck, half reached primary completion within 76 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 117. This study's 29 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 4, 2015
First posted
Mar 10, 2015
StartActual
Jul 31, 2015
Primary completionActual
Jan 19, 2018
CompletionActual
Dec 20, 2021
Results first posted
Apr 16, 2019
Last update
May 13, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 13, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02383966
Responsible party
Sponsor
First posted
Mar 10, 2015
Start date
Jul 31, 2015
Primary completion
Jan 19, 2018
Completion
Dec 20, 2021
Results posted
Apr 16, 2019
Last update
May 13, 2022

Study contacts

Medical Responsible
study director · Merck KGaA, Darmstadt, Germany

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cetuximab

Start the discussion